STTK:NASDAQ, Shattuck Labs, Inc.

STTK stock overview

Shattuck Labs, Inc. (STTK:NASDAQ) closed at $4.46 on November 20, 2026, down 1.98% on the day. The stock trades 46.5% below its 52-week high of $8.33 and 136.0% above its 52-week low of $1.89. Over the past year, it gained 119.7%. Shattuck Labs, Inc. is part of the Health Care sector.

Key figures

Price
$4.46
Day change
-1.98%
Volume
1,031,130
Average volume
1,189,504
Market cap
454M+
52-week range
$1.89 – $8.33
50-day average
$5.65
200-day average
$6.08

Price action over the past year

In 252 trading sessions since November 20, 2025, STTK closed higher on 127 days (50%). Its best day was January 7, 2026 (+20.60%) and its worst was June 8, 2026 (-14.85%). The stock moved 10% or more in a single session 10 times.

Recent signals

STTK news

About Shattuck Labs, Inc.

Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. The company's product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.

Similar stocks

Find more stocks like STTK with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.